Proteomics International Laboratories is nudging closer to commercialising its PromarkerD predictive test for diabetic kidney disease (DKD) after nailing down a payment rate of US$390.75 (AU$596) with the United States’ Centres for Medicare and Medicaid Services (CMS).

The Company says the CMS reimbursement price will enable affordable access to PromarkerD for millions of Americans living with Type 2 diabetes and help drive broad adoption of the test. Additionally, management notes many private insurers follow CMS pricing.

Article: Proteomics nails US pricing milestone for diabetes test